Liver (Hepatocellular) Cancer Prevention (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (05/26/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Evidence of Benefit

Revised text to state that strong evidence that hepatocellular cancer can be prevented is provided by a cluster randomized controlled trial of the immunization of 75,000 newborns. Also added text to state that after a median of about 25 years of follow-up, the incidence ratio of primary liver cancer in the vaccination-at-birth group to the control group was 0.16 (cited Qu et al. as reference 1).

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Evidence of Benefit

Next section >
About This PDQ Summary